- Home
- /
- Treatment
- /
- Page 4
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
Country | Product | Indication | Sponsor | Date |
---|---|---|---|---|
Baricitinib | Pediatric systemic lupus erythematosus | Eli Lilly and Company;Lilly Corporate Center;Indianapolis, Indiana, 46285 | November 2, 2017 | |
Live bacterial product consisting of defined consortia of Clostridium clusters live bacterial product consisting of defined consortia of Clostridium clusters | Prevention of recurrent Clostridium difficile infection in individuals with prior recurrent Clostridium difficile infection | Vedanta Biosciences, Inc.;19 Blackstone Street, Third Floor;Cambridge, Massachusetts, 02139 | November 2, 2017 | |
(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide | Hemoglobinuria | Achillion Pharmaceuticals, Inc;300 George Street;New Haven, Connecticut, 06511 | November 2, 2017 | |
Arimoclomol | Inclusion Body Myositis | Orphazyme ApS;Ole Maaloes Vej 3, 2200 Copenhagen; | November 2, 2017 | |
1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol | Progressive supranuclear palsy | Aprinoia Therapeutics;17F, No. 3 Yuanqu Street;Nangang District | November 1, 2017 | |
Vigabatrin and cosyntropin | West syndrome | West Therapeutic Development, LLC;540 Ziegler Drive;Grayslake, Illinois, 60030 | November 1, 2017 | |
(+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride | C1-inhibitor-dependent angioedema (including prevention and treatment of attacks) | BioCryst Pharmaceuticals, Inc.;4505 Emperor Blvd, Suite 200200;Durham, North Carolina, 27703 | November 1, 2017 | |
Indoximod | Metastatic Melanoma | NewLink Genetics Corporation;2503 South Loop Drive, Suite 5100;Ames, Iowa, 50010 | October 26, 2017 | |
Copper sulfate | Keratoconus | iVeena Drug Delivery Systems, Inc.;391 Chipeta Way, Suite I;Salt Lake City, Utah, 84108 | October 26, 2017 | |
Seribantumab | Non-small cell lung cancer | Merrimack Pharmaceuticals, Inc.;1 Kendall Square, Suite B7201;Cambridge, Massachusetts, 02139 | October 25, 2017 | |
9-cis,12-cis-11,11-D2-linoleic acid ethyl ester | PLA2G6-associated neurodegeneration | Retrotope, Inc.;4300 El Camino Real, Suite 201;Los Altos, California, 94022 | October 24, 2017 | |
Glepaglutide | Short bowel syndrome | Zealand Pharma A/S;36 Smedeland;Glostrup | October 20, 2017 | |
Glasdegib | Myelodysplastic syndrome | Pfizer, Inc.;445 Eastern Point Road;Groton, Connecticut, 06340 | October 20, 2017 | |
Valbenazine | Tourette syndrome | Neurocrine Biosciences, Inc.;12780 El Camino Real;San Diego, California, 92130 | October 19, 2017 | |
A strain of modified live probiotic bacterium Escherichia coli (E.coli) Nissle 1917 that has been modified to treat phenylketonuria by consuming phenylalanine within the gastrointestinal tract | Phenylketonuria | Synlogic, Inc.;200 Sidney Street, Suite 320;Cambridge, Massachusetts, 02139 | October 18, 2017 | |
Vatiquinone | Pontocerebellar Hypoplasia | BioElectron Technology Corporation;350 North Bernardo Avenue;Mountain View, California, 94043 | October 18, 2017 | |
Pracinostat | Acute myeloid leukaemia | Helsinn Birex Pharmaceuticals Ltd | October 16, 2017 | |
Synthetic cyclic 8 amino acid analogue of human unacylated ghrelin | Prader-Willi syndrome | Alizé Pharma | October 16, 2017 | |
Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8 | Mastocytosis | Envestia Limited | October 16, 2017 | |
Siplizumab | Treatment in solid organ transplantation | ITB-MED AB | October 16, 2017 | |
(S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid | Primary sclerosing cholangitis | Pharma Gateway AB | October 16, 2017 | |
2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine | Charcot-Marie-Tooth disease | Repositioning SAS | October 16, 2017 | |
5-amino-1-(2-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl 1H-indol-2-yl ketone mono[(S)-2-hydroxysuccinate] | Biliary tract cancer | Voisin Consulting S.A.R.L. | October 16, 2017 | |
Adenoviral vector of serotype 5 modified to contain a chimeric sequence consisting of a minimal urokinase-type plasminogen activator receptor promoter preceded by three Notch-responsive elements, and coated with oligopeptide end-modified poly (beta-amino) esters | Pancreatic Cancer | Sagetis Biotech, S.L. | October 16, 2017 | |
Autologous ex-vivo-expanded peripheral polyclonal lymphocytes enriched in activated natural killer cells | Multiple myeloma | CellProtect Nordic Pharmaceuticals AB | October 16, 2017 |